Blood Biomarkers Associated with Cognitive Decline in Early Stage and Drug-Naive Parkinson's Disease Patients.
Texto
Imagem
Documentos relacionados
studied some aspects of the validity of the MoCA for evaluating cognitive impairment in 66 Brazilian patients with PD, using the MDS-UPDRS, Hoehn-Yahr stage and MoCA test: 19.7 %
investigated the depressive symptoms of patients with Parkinson disease and mild cognitive impairment using several cognitive tests and the Beck..
Association of cerebrospinal fluid beta-amyloid 1-42, T-tau, P-tau181, and alpha-synuclein levels with clinical features of drug-naive patients with early Parkinson disease.
Unified Parkinson’s Disease Rating Scale (UPDRS) part III (motor signs), part V (Hoehn and Yahr PD staging sca- le), part VI (Schwab and England daily activities scale) and
between the evaluation of body image (My Body Image test) and self-concept (Factorial Self-concept Scale) with the stage of the disease (Modiied Hoehn and Yahr Scale), the level
he patients underwent a series of clini- cal tests, including: Uniied Parkinson’s Disease Rating Scale, modiied Hoehn and Yahr Staging Scale, modiied Schwab and England
Two movement disorders spe- cialists performed the following scale: Unified Parkinson’s disease rating score (UPDRS), the modified Hoehn and Yahr staging, Schwab and England
M: Male; F: Female; PD: Parkinson´s Disease; HD: Huntington´s disease; TS: Tourette´s syndrome; SCA3: Spinocerebellar Ataxia type 3; HY: Hoehn&Yahr Scale; YGTSS: Yale